Molecular imaging approaches: How can it help drug development?

Drug Discovery World

Volumn 10, Issue 4, 2009, Pages 33-38

  Sarkar, Susanta K ^a,b,c,d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Academy of Molecular Imaging   (United States)

^d International Society of Magnetic Resonance in Medicine

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ARTICLE; ATHEROSCLEROSIS; BLOOD FLOW; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG TARGETING; FUNCTIONAL MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TUMOR CELL; ULTRASOUND;

EID: 70350680469     PISSN: 14694344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Kola, I and Landis, J. Can the pharmaceutical industry reduce attrition rates. Nature Reviews Drug Discovery, 2004, 3, 711-715. (Pubitemid 39173511)
2. DiMasi, JA et al The price of innovation: new estimates of drug development costs. J. Health Econ, 2003, 2, 151-185.
3. Weissleder, R and Pittet, MJ. Imaging in the era of molecular oncology, Nature, 2008, 452, 580-589.
4. Willmann JK et al. Molecular Imaging in drug development, Nature Reviews: Drug Discovery, 2008, 7, 591-607.
5. Mansfield, P and Morris, PG. NMR Imaging in Biomedicine, Advances in Magnetic Resonance, Eds, J.S. Waugh, Academic Press, 1982.
6. Phelps, ME. PET: Molecular imaging and its biological applications, Springer, 2004.
7. Bushberg, JT et al eds. The essential physics of medical imaging, Lippincott, Williams, Wilkins, 2001.
8. Chance, B. Optical Methods, Ann. Rev. Biophys. Biophys. Chem, 1991, 20, 1-28.
9. Hayden, EC. Nature, 2009, 458, 686-687.
10. Backer, MV et al. Molecular Imaging of VEGF receptors in angiogenic vasculature with single chain VEGF-based probes, Nature Medicine, 13, 504-509.
11. Blankenberg, FG et al. Non-invasive assessment of tumor VEGF receptors in response to treatment with pazopanib: A molecular imaging study, Translational Oncology, 2010, 3, 000-000
12. Bergers, G and Benjamin, LE. Tumorigenesis and the angiogenic switch, Nat. Rev. Cancer, 2003, 2, 795-1794
13. Gillies, RJ et al. Applications of Magnetic Resonance in Model systems: tumor biology and physiology, Neoplasia, 2000, 139-151. (Pubitemid 30123185)
14. O'Connor, JPB et al. Quantitative imaging biomarkers in the clinical development of targeted therapeutics; current and future prospectives, The Lancet, 2008, 766-776.
15. Liu, G et al, Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors; results from a phase I study, J. Clin. Oncology, 2005, 23, 5464-5473. (Pubitemid 46300139)
16. Van den Abbeele, AD and Badawi, RD. Use of positron emission tomography in oncology and its potential role to assess response of imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs), Eur. J. Cancer, 2002, 38 (suppl 5), 60-65.
17. 18F-FDG small-animal PET, J. Nucl. Med., 2008, 49, 129-134.
18. Libby, P. Inflammation in atherosclerosis, Nature, 2002, 420, 868-874.
19. Herold, V et al. In vivo comparison of atherosclerotic plaque progression with vessel wall strain and blood flow velocity in apoE-/- mice with MR microscopy at 17.6 T., Magn,. Reson. Mater. Phy., 2009, 22, 159-166.
20. Lee, JMS et al. Multi-modal magnetic resonance imaging quantifies atherosclerosis and vascular dysfunction in patients with type 2 diabetes mellitus, Diab. Vasc. Dis. Res., 2007, 4, 44-48. (Pubitemid 46649073)
21. Hode, Y et al. A positron emission tomography (PET) study of cerebral dopamine D2 and serotonie-5HT2A receptor occupancy in patients treated with cyamemazine (Tercian). Psychopharmacology (Berl.), 2005, 180, 377-384.
22. Fischman, A et al. Pharmacokinetic imaging: a non-invasive method for determining drug distribution and action, Clin. Pharmacokinet., 2002, 41, 581-602.